Ask AI
GDMT in Cardio–Renal–Metabolic Disease

CE / CME

Expert Insights on Managing Cardio–Renal–Metabolic Diseases via GDMT

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

European Learners: 0.25 hours EBAC® effective education time

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Released: December 03, 2025

Expiration: December 02, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 68-year-old man with HFrEF and stage 3a/A2 CKD (eGFR 55 mL/min/1.73m2 and UACR 120 mg/g) is being considered for enrollment in a clinical trial evaluating an investigational aldosterone synthase inhibitor (ASI). Which of the following statements best reflects a potential advantage of ASIs over MRAs in the management of patients with CKM conditions?